Related Experiment Videos
Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening
Peizhi Luo1, Robert J Hayes, Cheryl Chan
1Xencor, Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, USA.
Protein Science : a Publication of the Protein Society
|April 23, 2002
Summary
Computational protein design enhanced granulocyte-colony stimulating factor (G-CSF) stability and shelf life. Developed G-CSF analogs show improved pharmacokinetics, offering potential for better drug delivery and patient outcomes.
Area of Science:
- Biotechnology
- Protein Engineering
- Computational Biology
Background:
- Granulocyte-colony stimulating factor (G-CSF) is crucial for preventing chemotherapy-induced neutropenia.
- Current G-CSF formulations suffer from limited stability, requiring strict storage and daily injections due to poor oral absorption.
- There is a significant need for G-CSF analogs with improved pharmacological properties and delivery methods.
Purpose of the Study:
- To computationally design and develop granulocyte-colony stimulating factor (G-CSF) analogs with enhanced physicochemical and pharmacokinetic properties.
- To improve the stability, shelf life, and systemic exposure of G-CSF through targeted protein engineering.
- To validate the efficacy of computationally designed G-CSF analogs in preclinical models.
Main Methods:
- Utilized an ultrahigh throughput computational screening method to optimize G-CSF core residues.
- Employed homology modeling based on bovine G-CSF to guide protein design.
- Screened 25-34 residue core designs, resulting in sequences with 10-14 mutations.
- Conducted biophysical characterization, in vitro cell proliferation assays, and in vivo studies in a neutropenic mouse model.
- Performed pharmacokinetic studies in monkeys following subcutaneous administration.
Main Results:
- Designed G-CSF analogs exhibited enhanced thermal stability (up to 13°C increase).
- Achieved a five-to 10-fold improvement in shelf life for the engineered proteins.
- Demonstrated biological activity in cell proliferation assays and efficacy in a neutropenic mouse model.
- Subcutaneous injection of analogs in monkeys resulted in significantly greater systemic exposure, suggesting improved absorption.
Conclusions:
- The computational screening method is effective for developing improved pharmaceutical proteins.
- Engineered G-CSF analogs possess superior stability and pharmacokinetic profiles compared to the wild-type.
- This approach offers a powerful tool for protein design, potentially leading to more robust and effective biotherapeutics.
- The developed analogs hold promise for enhanced drug delivery systems and improved clinical outcomes in managing neutropenia.